Welcome to CSNpharm! For Research Use Only!
Home
+1-708-781-1677
sales@csnpharm.com
HIF
| Cat. No. | Product Name | CAS No. | Information |
|---|---|---|---|
| CSN18648 | Vadadustat | 1000025-07-9 | Vadadustat is used for treatment of anemia and chronic kidney disease by Leading to stabilization and increased levels of HIF and improving production of hemoglobin and red blood cells (RBCs) while maintaining normal levels of erythropoietin (EPO). |
| CSN24188 | TP0463518 | 1558021-37-6 | TP0463518 is a potent HIF-PHD inhibitor with Ki value of 5.3 nM for PHD2, and also inhibited human PHD1/3 with IC50 values of 18 and 63 nM. |
| CSN18362 | THS-044 | 62054-67-5 | THS-044 binding stabilizes the HIF2 PAS-B folded state for regulating HIF2 activity in endogenous and clinical settings |
| CSN19042 | SYP-5 | 1384268-04-5 | SYP-5 is a HIF-1 inhibitor suppresses tumor cells invasion and angiogenesis |
| CSN18393 | PX-478 Dihydrobromide | 685898-44-6 | PX-478 target on HIF-1α, which can selectively inhibit the hypoxia-induced increase in HIF-1a protein. |
| CSN17993 | PT-2385 | 1672665-49-4 | PT2385 is an inhibitor of hypoxia inducible factor HIF-2 alpha with antineoplastic effect |
| CSN17994 | PT-2385 R-Enantiomer | 1672666-67-9 | PT-2385 R-enantiomer is the R-enantiomer of PT-2385 which is a potent HIF-2 inhibitor and is a potential anticancer agent |
| CSN20370 | PHD-1 Inhibitor C54 | 2009344-53-8 | PHD-1 inhibitor C54 is a 4-1,2,4triazolo1,5-apyridin-5-ylbenzonitrile-based inhibitor of the hypoxia-inducible factor (HIF) prolylhydroxylase domain-1 (PHD-1). It exhibits reasonable peripheral exposure but poor brain levels (Kp,uu 0.02 and BP 0.03). |
| CSN20369 | PHD-1 Inhibitor C53 | 2009345-20-2 | PHD-1 inhibitor C53 is a 4-1,2,4triazolo1,5-apyridin-5-ylbenzonitrile-based inhibitor of the hypoxia-inducible factor (HIF) prolylhydroxylase domain-1 (PHD-1). It exhibits excellent peripheral exposure, but does not partition well into the brain (Kp,uu 0.39 and BP 0.21). |
| CSN20368 | PHD-1 Inhibitor C39 | 2009343-19-3 | PHD-1 inhibitor C39 is a 4-1,2,4triazolo1,5-apyridin-5-ylbenzonitrile-based inhibitor of the hypoxia-inducible factor (HIF) prolylhydroxylase domain-1 (PHD-1) with high solubility and permeability. |
| CSN20367 | PHD-1 Inhibitor C17 | 2009343-14-8 | PHD-1 inhibitor C17 is an early lead compound of 4-1,2,4triazolo1,5-apyridin-5-ylbenzonitrile-based inhibitors of the hypoxia-inducible factor (HIF) prolylhydroxylase domain-1 (PHD-1) showing a moderate rate of microsomal turnover in vitro. |
| CSN11607 | Oltipraz | 64224-21-1 | Oltipraz can inhibit the insulin-activated HIF-1 (IC50 10 M) in a time-dependent manner. |
| CSN14671 | Moracin O | 123702-97-6 | Moracin O and moracin P exhibit potent in vitro inhibitory activity against hypoxia-inducible factor HIF-1 which is a key mediator during adaptation of cancer cells to tumour hypoxia |
| CSN16636 | ML228 | 1357171-62-0 | ML228 is an activator of the Hypoxia Inducible Factor HIF pathway and potently activate HIF in vitro as well as its downstream target VEGF |
| CSN19680 | MK-8617 | 1187990-87-9 | MK-8617 is a potent, selective, orally bioavailabl pan-inhibitor of hypoxia-inducible factor prolyl hydroxylase 1−3 (HIF PHD1−3), inhibiting PHD1, 2, 3 with IC50s of 1.0, 1.0 and 14 nM, respectively. |
| CSN20474 | LW6 | 934593-90-5 | LW6 is an inhibitor of HIF-1 with IC50 of 4.4 μM. |
| CSN17251 | KC7F2 | 927822-86-4 | KC7F2 is a selective HIF-1 transcription inhibitor with IC50 of 20 M in a cell-based assay |
| CSN17541 | JNJ-42041935 | 1193383-09-3 | JNJ-42041935 is a selective inhibitor of prolyl hydroxylase (PHD) with the pKis of 7.91 0.04, 7.29 0.05, and 7.65 0.09 for PHD1, PHD2, and PHD3, respectively. |
| CSN16064 | IOX2 | 931398-72-0 | IOX2 is a selective inhibitor of the hypoxia inducible factor HIF Prolyl-Hydroxylases PHD and active in cells with IC50 value of 21 nM for PHD2ELGN-1 and no inhibition at FIH20uM |
| CSN20256 | IDF-11774 | 1429054-28-3 | IDF-11774 is a hypoxia-inducible factor HIF-1 inhibitor which regulates cancer metabolism thereby suppressing tumor growth |
| CSN18038 | HIF-2α-IN-1 | 1799948-06-3 | HIF-2-IN-1 is a HIF-2 inhibitor has an IC50 of less than 500 nM in HIF-2 scintillation proximity assay |
| CSN20613 | GSK360A | 931399-19-8 | GSK360A is an active HIF-PHD inhibitor with systemic and local effects by stabilizing HIF-1 signaling and can improve long-term ventricular function |
| CSN16866 | FG-2216 | 223387-75-5 | FG-2216 is a potent HIF-prolyl hydroxylase inhibitor with IC50 of 39 M for PHD2 enzyme orally bioavailable and induced significant and reversible Epo induction in vivo |
| CSN22394 | Enarodustat | 1262132-81-9 | Enarodustat is a potent and orally active factor prolyl hydroxylase inhibitor with an EC50 of 022 M Enarodustat has entered clinical trial for renal anemia |
| CSN17599 | EL-102 | 1233948-61-2 | EL102 is an inhibitor of HIF1 Which can inhibit tubulin polymerisation and decreased microtubule stability |
| CSN20491 | Echinomycin | 512-64-1 | Echinomycin is a highly potent and selective HIF-1 inhibitor IC50 294 pM which selectively inhibits HIF-1 binding to the VEGF promoter without affecting the binding of AP-1 or NF-B |
| CSN10851 | DMOG | 89464-63-1 | Dimethyloxallyl glycine is a cell permeable competitive inhibitor of HIF-PH HIF-1 prolyl hydroxylase |
| CSN16738 | Ciclopirox | 29342-05-0 | Ciclopirox inhibits iron-dependent enzymes PHD2 pIC50 58 and deoxyhypusine hydroxylase It is an antifungal and iron-chelating agent |
| CSN17588 | BAY 87-2243 | 1227158-85-1 | BAY 87-2243 is a highly potent and selective inhibitor of hypoxia-induced HIF-1 activation |
| CSN19253 | 2-Methoxyestradiol | 362-07-2 | 2-methoxyestradiol is a natural metabolite of estrogen that is known to inhibit HIF-1 alpha with an IC50 of 0.71 ± 0.11 μM for the inhibition of BPAEC migration. |
| CSN23782 | Desidustat | 1616690-16-4 |
+1-708-781-1677
+1-708-286-6026
sales@csnpharm.com
